Effects of Buspirone in Opiate Withdrawal

Completed · Phase 4

Conditions studied: Heroin Dependence

In brief

Dependence on heroin is a major public health problem because of its association with criminality, law enforcement costs and healthcare costs. Managed withdrawal is a required first step for a long term drug-free treatment of heroin addicts. Methadone and clonidine have been the mainstay of treatment for the relief of heroin withdrawal symptoms but both have limitations. The purpose of this study was to evaluate the efficacy of buspirone in the alleviation of the withdrawal symptoms experienced by heroin addicts when they stop using heroin. Buspirone is a non opiate drug with no abuse potential, no sedating effects and no withdrawal symptoms.

Key facts

Study ID

NCT00326235

Run by

National Institute on Drug Abuse (NIDA)

Starts

2002-01-01

Expected to finish

2004-07-01

Last updated by the study team

2017-01-12

Who can join

Age: 25 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• fulfilled DSM IV diagnostic criteria for opioid dependence
• used heroin daily for at least the prior 6 months with claimed heroin use of at least 2.5g/week
• physical dependence on opiates as determined by history and observation
• admission urine samples demonstrating heroin use
• expressed willingness to participate in a randomized, double-blind, placebo-controlled study for 14 days.

You may not qualify if…

• current or past Axis I psychiatric disorder other than opioid dependence
• evidence of significant neurological, gastrointestinal, hepatic, cardiovascular, renal, endocrine or hematologic disease
• seropositive status for the human immunodeficiency virus

Where it is running

• VA New York Harbor Healthcare System - Brooklyn Campus — Brooklyn, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.